Highlights

  • XRF Scientific shares rose 4.14% to AUD 1.88 on 15 April 2026 following quarterly results.
  • March quarter revenue increased 13.8% year-on-year to $15.8 million.
  • Profit before tax grew 10.7% to $3.7 million for the quarter.
  • Year-to-date revenue reached $47.0 million, up 10.6% for nine months.
  • Favourable international demand, particularly in Asia, drove growth across divisions.

XRF Scientific Limited (ASX:XRF) shares advanced 4.14% to AUD 1.88 on 15 April 2026, extending its 12-month gain to 12.20%. Today’s upward movement follows the release of the company’s March 2026 quarterly trading report, which highlighted solid growth in both revenue and profitability, alongside favourable demand across its global markets.

The latest results reflect continued momentum in XRF Scientific’s operations, supported by international sales growth, robust consumables demand, and increased activity across its capital equipment and precious metals segments.

Company Overview: Global Supplier of Analytical Solutions

XRF Scientific is an Australia-based company engaged in the manufacture of equipment and chemicals used in sample preparation for analysis. Its products are widely used across industries such as mining, construction materials, chemicals, and petrochemicals.

The company operates manufacturing, sales, and support facilities across multiple regions, including Australia, Europe, Canada, and India, supported by a global distribution network. Its customer base includes large multinational companies operating in resource and industrial sectors, as well as commercial laboratories.

XRF’s technologies play a critical role in quality control and process optimisation, helping customers improve productivity, enhance product quality, and reduce operational inefficiencies.

Quarterly Revenue and Profit Show Steady Growth

For the quarter ended 31 March 2026, XRF Scientific reported revenue of $15.8 million, representing a 13.8% increase compared to $13.9 million in the corresponding period last year.

Profit before tax for the quarter rose to $3.7 million, up 10.7% from $3.4 million in the March 2025 quarter. The company described the period as positive, with all business divisions contributing to the overall performance.

On a year-to-date basis, covering the nine months to 31 March 2026, revenue reached $47.0 million, reflecting a 10.6% increase from $42.4 million in the prior corresponding period. Profit before tax for the same period rose to $11.2 million, up 8.5% from $10.3 million.

These results indicate consistent growth across both quarterly and year-to-date metrics, reinforcing the company’s operational momentum.

International Sales Drive Growth Momentum

A key driver of the company’s performance during the quarter was favourable international demand, particularly from Asian markets. This growth trend highlights the increasing contribution of overseas markets to XRF Scientific’s revenue base.

The company also noted that the results included costs associated with expansion initiatives, including the setup of its new office in India. Despite these additional costs, overall performance remained positive, supported by favourable sales activity.

The India office became operational during the quarter, with initial customer orders received in March. These orders are expected to be invoiced in the June 2026 quarter, indicating potential revenue contribution in the near term.

Consumables Segment Delivers Robust Performance

The consumables segment continued to perform favourably, generating $4.8 million in sales during the quarter, compared to $4.4 million in the previous corresponding period.

The company highlighted that it closed the quarter with a record month in March, both in terms of sales revenue and product volumes. This favourable finish underscores the underlying demand for its consumable products.

In addition, XRF reported holding approximately $1 million in additional orders that had not yet been processed as of 31 March 2026. These orders are expected to be recognised in the June quarter, reflecting ongoing sales momentum.

Capital Equipment Sales Strengthen with Increased Activity

Capital equipment sales also contributed positively to the quarterly performance, with revenue reaching $5.4 million compared to $4.5 million in the prior corresponding period.

A notable contributor within this segment was the Orbis crushers product line, which recorded sales of $2.5 million during the quarter. The company indicated that demand for these products is being driven by activity in the gold sector, with positive momentum expected to continue into the June quarter.

The quarter also marked the shipment of the first next-generation xrFuse 1 and xrFuse 2 units to customers, supported by a fully operational new production line. Additionally, revenue from the xrTGA product line continued to grow, with increasing order volumes and repeat customer demand.

The company also noted that multiple product development initiatives are ongoing, with further product releases expected within the current calendar year.

Precious Metals Segment Shows Positive Trends

The precious metals segment delivered sales of $5.6 million for the quarter, up from $4.9 million in the prior corresponding period.

During the quarter, platinum prices declined from their peak levels in January 2026. According to the company, this price movement contributed to increased demand for new products toward the end of the quarter.

These dynamic highlights the sensitivity of demand within this segment to fluctuations in commodity prices, which can influence customer purchasing behaviour.

Operational Expansion and Future Focus

The establishment of the company’s new office in India represents a key step in its international expansion strategy. The facility is expected to support further growth in regional sales, particularly given the positive initial response from customers.

Looking ahead, XRF Scientific indicated that it will continue to focus on expanding international sales, advancing product development initiatives, and exploring potential merger and acquisition opportunities during the June 2026 quarter.

These strategic priorities suggest a continued emphasis on growth and market expansion.

What This Means for Investors?

The March 2026 quarterly update reflects steady growth across XRF Scientific’s core business segments, supported by favourable international demand and expanding product activity.

The increase in both revenue and profit, combined with record sales momentum and unprocessed order backlog, appears to be driving the positive share price movement observed on 15 April 2026.

Additionally, the company’s expansion into India and ongoing product development initiatives indicate a forward-looking growth strategy.

Investors are likely to monitor the conversion of the current order backlog into revenue, continued performance in international markets, and updates on new product releases in the coming quarters.